Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies

Abstract

The four serotypes of dengue virus (DENV) cause the most important and rapidly emerging arboviral diseases in humans. The recent phase 2b and 3 studies of a tetravalent dengue vaccine reported a moderate efficacy despite the presence of neutralizing antibodies, highlighting the need for a better understanding of neutralizing antibodies in polyclonal human sera. Certain type-specific (TS) antibodies were recently discovered to account for the monotypic neutralizing activity and protection after primary DENV infection. The nature of neutralizing antibodies after secondary DENV infection remains largely unknown. In this study, we examined sera from 10 vaccinees with well-documented exposure to first and second DENV serotypes through heterotypic immunization with live-attenuated vaccines. Higher serum IgG avidities to both exposed and nonexposed serotypes were found after secondary immunization than after primary immunization. Using a two-step depletion protocol to remove different anti-envelope antibodies, including group-reactive (GR) and complex-reactive (CR) antibodies separately, we found GR and CR antibodies together contributed to more than 50% of neutralizing activities against multiple serotypes after secondary immunization. Similar findings were demonstrated in patients after secondary infection. Anti-envelope antibodies recognizing previously exposed serotypes consisted of a large proportion of GR antibodies, CR antibodies, and a small proportion of TS antibodies, whereas those recognizing nonexposed serotypes consisted of GR and CR antibodies. These findings have implications for sequential heterotypic immunization or primary immunization of DENV-primed individuals as alternative strategies for DENV vaccination. The complexity of neutralizing antibodies after secondary infection provides new insights into the difficulty of their application as surrogates of protection. IMPORTANCEThe four serotypes of dengue virus (DENV) are the leading cause of arboviral diseases in humans. Despite the presence of neutralizing antibodies, a moderate efficacy was recently reported in phase 2b and 3 trials of a dengue vaccine; a better understanding of neutralizing antibodies in polyclonal human sera is urgently needed. We studied vaccinees who received heterotypic immunization of live-attenuated vaccines, as they were known to have received the first and second DENV serotype exposures. We found anti-envelope antibodies consist of group-reactive (GR), complex-reactive (CR), and type-specific (TS) antibodies, and that both GR and CR antibodies contribute significantly to multitypic neutralizing activities after secondary DENV immunization. These findings have implications for alternative strategies for DENV vaccination. Certain TS antibodies were recently discovered to contribute to the monotypic neutralizing activity and protection after primary DENV infection; our findings of the complexity of neutralizing activities after secondary immunization/infection provide new insights for neutralizing antibodies as surroga...

Dengue vaccines: Are they safe for travelers?

“…Primary and secondary infections with NIAID monotypic DENV 1, 2 and 4 vaccines produced the same antibody reactivity to envelop DENV epitopes as were observed after infections with wild-type DENV [35]. CD8 þ T cell responses after TV003 were comparable to those following natural dengue infections.…”

B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts

“…Given that all the patients were previously exposed to DENV and that the four DENV serotypes share high genomic sequence homology (5), we were not surprised by the large number of fully cross-reactive MAbs in our panel. A recently published report examining secondary responses in dengue vaccinees ably demonstrates the importance of cross-reactive antibodies and the impact of their depletion on serum neutralization and binding titers (45). Our data showing the large abundance of cross-reactive MAbs during natural dengue virus infection reiterates the significance of broadly neutralizing responses to vaccine design efforts.…”

Dengue: knowledge gaps, unmet needs, and research priorities

“…89 Many bind around the fusion loop region on domain II (EDII); nonetheless, some antibodies that bind this region are potently neutralizing. 90,91 Following both primary and secondary infection, the most potently neutralizing antibodies are virion-specific and often bind across dimers, contacting up to three monomers simultaneously, thus throwing a ‘wrench’ into the DENV E protein machinery that successfully prevents fusion. 75,92–95 These antibodies bind multiple sites on the E protein, including regions of EDIII, the fusion loop, and the hinge of EDI/II.…”